Mostrar o rexistro simple do ítem

dc.contributor.authorGalian-Gay, L.
dc.contributor.authorEscalona Silva, R.A.
dc.contributor.authorTeixidó-Turà, G.
dc.contributor.authorCasas, G.
dc.contributor.authorFerrer-Sistach, E.
dc.contributor.authorMitroi, C.
dc.contributor.authorMingo, S.
dc.contributor.authorMonivas, V.
dc.contributor.authorSaura, D.
dc.contributor.authorVidal, B.
dc.contributor.authorTrasca, L.
dc.contributor.authorMoral, S.
dc.contributor.authorCalvo, F.
dc.contributor.authorCastiñeira Busto, María 
dc.contributor.authorSánchez, V.
dc.contributor.authorGonzalez, A.
dc.contributor.authorGuzman, G.
dc.contributor.authorMora, M.N.
dc.contributor.authorArnau Vives, M.
dc.contributor.authorPeteiro Vazquez, Jesus
dc.contributor.authorBouzas, A.
dc.contributor.authorMas-Stachurska, A.
dc.contributor.authorGonzález-Alujas, T.
dc.contributor.authorGutiérrez, L.
dc.contributor.authorFernandez-Galera, R.
dc.contributor.authorValente, F.
dc.contributor.authorGuala, A.
dc.contributor.authorRuiz-Muñoz, A.
dc.contributor.authorAvilés, C.A.S.
dc.contributor.authorPalomares, J.F.R.
dc.contributor.authorFerreira, I.
dc.contributor.authorEvangelista, A.
dc.date.accessioned2025-08-26T10:55:54Z
dc.date.available2025-08-26T10:55:54Z
dc.date.issued2022
dc.identifier.citationGalian-Gay L, Escalona Silva RA, Teixidó-Turà G, Casas G, Ferrer-Sistach E, Mitroi C, et al. Prognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits. Frontiers in Cardiovascular Medicine. 2022;9.
dc.identifier.issn2297-055X
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/63418e6d29543f68c1401293*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20750
dc.description.abstractObjectives: To determine the risk of mortality and need for aortic valve replacement (AVR) in patients with low-flow low-gradient (LFLG) aortic stenosis (AS). Methods: A longitudinal multicentre study including consecutive patients with severe AS (aortic valve area [AVA] < 1.0 cm2) and normal left ventricular ejection fraction (LVEF). Patients were classified as: high-gradient (HG, mean gradient ? 40 mmHg), normal-flow low-gradient (NFLG, mean gradient < 40 mmHg, indexed systolic volume (SVi) > 35 ml/m2) and LFLG (mean gradient < 40 mmHg, SVi ? 35 ml/m2). Results: Of 1,391 patients, 147 (10.5%) had LFLG, 752 (54.1%) HG, and 492 (35.4%) NFLG. Echocardiographic parameters of the LFLG group showed similar AVA to the HG group but with less severity in the dimensionless index, calcification, and hypertrophy. The HG group required AVR earlier than NFLG (p < 0.001) and LFLG (p < 0.001), with no differences between LFLG and NFLG groups (p = 0.358). Overall mortality was 27.7% (CI 95% 25.3-30.1) with no differences among groups (p = 0.319). The impact of AVR in terms of overall mortality reduction was observed the most in patients with HG (hazard ratio [HR]: 0.17; 95% CI: 0.12-0.23; p < 0.001), followed by patients with LFLG (HR: 0.25; 95% CI: 0.13-0.49; p < 0.001), and finally patients with NFLG (HR: 0.29; 95% CI: 0.20-0.44; p < 0.001), with a risk reduction of 84, 75, and 71%, respectively. Conclusions: Paradoxical LFLG AS affects 10.5% of severe AS, and has a lower need for AVR than the HG group and similar to the NFLG group, with no differences in mortality. AVR had a lower impact on LFLG AS compared with HG AS. Therefore, the findings of the present study showed LFLG AS to have an intermediate clinical risk profile between the HG and NFHG groups.en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titlePrognosis of Paradoxical Low-Flow Low-Gradient Aortic Stenosis: A Severe, Non-critical Form, With Surgical Treatment Benefits*
dc.typeArticleen
dc.authorsophosGalian-Gay, A. L.
dc.authorsophosEscalona Silva, R. A.
dc.authorsophosTeixidó-Turà, G.
dc.authorsophosCasas, G.
dc.authorsophosFerrer-Sistach, E.
dc.authorsophosMitroi, C.
dc.authorsophosMingo, S.
dc.authorsophosMonivas, V.
dc.authorsophosSaura, D.
dc.authorsophosVidal, B.
dc.authorsophosTrasca, L.
dc.authorsophosMoral, S.
dc.authorsophosCalvo, F.
dc.authorsophosCastiñeira Busto, M.
dc.authorsophosSánchez, V.
dc.authorsophosGonzalez, A.
dc.authorsophosGuzman, G.
dc.authorsophosMora, M. N.
dc.authorsophosArnau Vives, M.
dc.authorsophosPeteiro, J.
dc.authorsophosBouzas, A.
dc.authorsophosMas-Stachurska, A.
dc.authorsophosGonzález-Alujas, T.
dc.authorsophosGutiérrez, L.
dc.authorsophosFernandez-Galera, R.
dc.authorsophosValente, F.
dc.authorsophosGuala, A.
dc.authorsophosRuiz-Muñoz, A.
dc.authorsophosAvilés, C. A. S.
dc.authorsophosPalomares, J. F. R.
dc.authorsophosFerreira, I.
dc.authorsophosEvangelista
dc.identifier.doi10.3389/fcvm.2022.852954
dc.identifier.sophos63418e6d29543f68c1401293
dc.journal.titleFrontiers in Cardiovascular Medicine*
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fcvm.2022.852954/pdf;https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.852954/pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Vigoes
dc.subject.keywordCHUVIes
dc.subject.keywordAS Coruñaes
dc.subject.keywordCHUACes
dc.subject.keywordINIBICes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number9


Ficheiros no ítem

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem

Atribución 4.0 Internacional
A non ser que se indique outra cousa, a licenza do ítem descríbese comoAtribución 4.0 Internacional